PDL BioPharma, Inc. (PDLI) belonging to the Medical sector has declined -1.33% and closed its last trading session at $2.22.
The company reported its EPS on 03/01/2017. Currently, the stock has a 1 Year Price Target of $3.5.
The consensus recommendation, according to Zacks Investment research, is 2. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2 respectively.
PDL BioPharma, Inc. on 03/01/2017 reported its EPS as $0.29 with the analysts projecting the EPS of the stock as $0.09. The company beat the analyst EPS Estimate with the difference of $0.2. This shows a surprise factor of 222.2%.
Many analysts have provided their estimated foresights on PDL BioPharma, Inc. Earnings, with 2 analysts believing the company would generate an Average Estimate of $0.05.
Whereas they predicted High and Low Earnings Estimate as $0.05 and $0.05 respectively. While in the same Quarter Previous year, the Actual EPS was $0.34.
Analysts are also projecting an Average Revenue Estimate for PDL BioPharma, Inc. as $2000 in the Current Quarter. This estimate is provided by 50230 analysts.
The High Revenue estimate is predicted as 54.05 Million, while the Low Revenue Estimate prediction stands at 46.42 Million. The company’s last year sales total was 103.12 Million.
For the Current Quarter, the growth estimate for PDL BioPharma, Inc. is -85.3%, while for the Next Quarter the stock growth estimate is 66.7%.
In the past 5 years, the stock showed growth of 15.33% per annum. While for the next 5 years, the growth estimate is 14%.
Insider Trades for PDL BioPharma, Inc. show that the latest trade was made on 23 Mar 2017 where Garcia (Peter S), the Chief Financial Officer completed a transaction type “Buy” in which 5000 shares were traded at a price of $1.98.
PDL BioPharma, Inc. (PDLI) has the market capitalization of $372.47 Million. The company rocked its 52-Week High of $3.78 and touched its 52-Week Low of $1.93.
The stock has Return on Assets (ROA) of 5.6 percent. Return on Equity (ROE) stands at 8.5% and Return on Investment (ROI) of 8.3 percent.
The stock is currently showing YTD performance of 4.72 Percent. The company has Beta Value of 0.56 and ATR value of 0.09. The Weekly and Monthly Volatility stands at 3.97% and 4.28%.